CG Oncology, Inc.
corporate_fare Company Profile
CG Oncology, Inc. (NASDAQ:CGON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CGON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CGON spans 4, 8-K, 144, 10-Q.
Recent high-impact activity:
- CG Oncology CEO Arthur Kuan Buys $2.37M of Stock in Open Market
- CG Oncology's PIVOT-006 Hits Primary Endpoint: 68% Recurrence Risk Cut, BLA Set for March 2027
- Phase 3 Win: Cretostimogene Cuts Bladder Cancer Recurrence Risk 68%
- Q3 Net Loss Widens to $56.9M as PIVOT-006 Topline Data Nears This Month
- Former President & COO Ambaw Bellete Plans $696K Stock Sale, Extending $22.5M Post-Departure Liquidation
Financial Snapshot
Short Interest & Short Volume
10.96 days to coverFINRA reported short interest of 9,215,844 shares in CGON as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 11.0 days to cover at its recent average daily volume. On November 20, 2026, 54.9% of CGON volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CGON, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
ATM Program Upsized by $500M · Immediate Dilution of $55.92 Per Share
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →